Rockcliffe Labs Inc. has launched Canada”s first dedicated venture-building platform for biotechnology and life sciences as of October 19, 2025. Based in Toronto, this initiative aims to transform innovative scientific discoveries into scalable companies, with a goal of creating 100 ventures over the next ten years.
The mission of Rockcliffe Labs is to industrialize the process of company creation. Rather than focusing on isolated success stories, the platform applies a structured system designed to produce a diverse range of globally relevant ventures. Each new company will target a specific global challenge, aligning intellectual property, entrepreneurial leadership, and capital from the outset. By committing to the creation of 100 companies, Rockcliffe Labs enhances discipline and scalability, ensuring that Canadian research translates into competitive businesses capable of attracting partnerships and funding.
In conjunction with its launch, Rockcliffe Labs has partnered with a prominent Canadian university, which will hold a 7.5% ongoing interest in the ventures developed through a shared licensing program. This partnership grants Rockcliffe preferential access to a range of intellectual properties, including novel biomarkers and therapeutic targets. The 7.5% equity structure allows the university to benefit from long-term value generation while ensuring streamlined licensing terms for Rockcliffe.
Despite Canada”s leadership in research output within biotechnology and life sciences, the nation has historically struggled to convert these discoveries into global enterprises. Rockcliffe Labs aims to bridge this commercialization gap by integrating operational expertise and commercial partnerships directly into the scientific innovation framework. This approach ensures that groundbreaking Canadian research is not only published but also transformed into businesses that can compete on the international stage, thereby fostering economic growth and attracting global investment.
The roadmap for building 100 companies is organized around four interconnected venture-building factories, each designed to generate approximately 20-30 ventures within the decade. The Rockcliffe Venture Model utilizes a closed-loop process for venture creation, systematically establishing companies with solid scientific and commercial foundations.
Rockcliffe Labs has also acquired Algae-C Inc., a biotechnology firm with a portfolio of 14 patents and over 600 bioactive compounds derived from algae. This acquisition lays the groundwork for Rockcliffe”s biomanufacturing vertical, demonstrating the potential for the kinds of ventures it plans to replicate throughout its 100-company roadmap.
The structured approach to achieving the goal of 100 companies ensures resilience and scalability, creating a portfolio effect across the ventures. Rockcliffe Labs intends to maintain close collaborations with universities, research institutions, and government initiatives, with the recently established university partnership formalizing this strategy.
Applications for the inaugural Rockcliffe Labs venture-building program are set to open in early 2026. Selected participants will include entrepreneurs and scientific founders integrated into Rockcliffe”s venture creation model, gaining access to the platform”s resources, licensing partnerships, and investor networks, positioning each venture for global expansion.
Ultimately, the establishment of Rockcliffe Labs and its ambitious plan to create 100 companies aims to address critical global challenges across health, agriculture, and sustainability.
This press release contains forward-looking statements regarding the 100-company plan and long-term outcomes, which are subject to risks and uncertainties. Rockcliffe Labs does not commit to updating these statements unless legally required. This announcement does not constitute an offer to sell or solicit securities in any jurisdiction, as any securities offering will occur only through applicable legal documents.
For media inquiries, please contact Rockcliffe Labs Inc. via email at [email protected] or visit www.rockcliffelabs.com.
